Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imatinib in Refractory Systemic Sclerosis
NCT00506831Phase 2Completed
- Sponsor
- Stanford University
- Start
- Jul 2007
- Primary completion
- Sep 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of imatinib in systemic sclerosis (SSc), sponsored by Stanford University. Primary endpoint: Modified Rodnan Skin Score at 6 months. Started Jul 2007; status: completed.
02
Drugs
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on NCT00506831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00506831.